Asset Details
Do you wish to reserve the book?
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
Do you wish to request the book?
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
2020
Overview
With the potential development of new disease-modifying Alzheimer’s disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid β positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid β-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by
18
F-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.
Plasma pTau181 concentrations are elevated specifically in patients diagnosed with Alzheimer’s disease compared to those diagnosed with frontotemporal lobar degeneration or elderly controls, supporting its further development as a blood-based biomarker for AD.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Aged
/ Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - diagnosis
/ Amyloid
/ Amyloid beta-Peptides - blood
/ Amyloid beta-Peptides - cerebrospinal fluid
/ Aphasia
/ Autopsy
/ Biochemistry & Molecular Biology
/ Biomarkers - cerebrospinal fluid
/ Biomedical and Life Sciences
/ Blood
/ Dementia
/ Female
/ Frontotemporal Lobar Degeneration - blood
/ Frontotemporal Lobar Degeneration - diagnosis
/ Frontotemporal Lobar Degeneration - genetics
/ Frontotemporal Lobar Degeneration - pathology
/ Gray Matter - diagnostic imaging
/ Humans
/ Male
/ Medicine
/ Mutation
/ Neurofilament Proteins - blood
/ Plasma
/ Positron emission tomography
